Showing results (11-20 of 38) with videos related to
Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|May 6, 2003
Non-peptide alphavbeta3 antagonists. Part 6: design and synthesis of alphavbeta3 antagonists containing a pyridone or pyrazinone central scaffoldMichael J Breslin, Mark E Duggan, Wasyl Halczenko, et al.The Journal of Pharmacology and Experimental Therapeutics|January 30, 2004
A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrainJulie A O'Brien, Wei Lemaire, Marion Wittmann, et al.Journal of Medicinal Chemistry|April 5, 2018
Toward β-Secretase-1 Inhibitors with Improved Isoform SelectivityPatrik Johansson, Karin Kaspersson, Ian K Gurrell, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 29, 2015
Selective inhibition of KCC2 leads to hyperexcitability and epileptiform discharges in hippocampal slices and in vivoSudhir Sivakumaran, Ross A Cardarelli, Jamie Maguire, et al.Bioorganic & Medicinal Chemistry Letters|September 11, 2004
Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivativeMichael J Breslin, Mark E Duggan, Wasyl Halczenko, et al.Neuropharmacology|July 22, 2017
Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154Robert W Gould, Michael D Grannan, Barak W Gunter, et al.Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacementsKaren M Brashear, Cecilia A Hunt, Brian T Kucer, et al.Bioorganic & Medicinal Chemistry Letters|January 11, 2007
Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHAZhijian Zhao, David D Wisnoski, Julie A O'Brien, et al.Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimeticsPaul J Coleman, Ben C Askew, John H Hutchinson, et al.Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptideRobert S Meissner, James J Perkins, Le T Duong, et al.Pageof 4